FDA Announces Public Workshop to Reconsider Mandatory Prescriber Education for Opioids
WASHINGTON, D.C. — The following quote is attributed to Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research:
Read MoreOpioids
Department of Drug and Alcohol Programs Visits Reading Hospital
READING, PA — Department of Drug and Alcohol Programs (DDAP) Secretary Jen Smith this week visited Reading Hospital – Tower Health to highlight successes within their warm handoff program and …
Read More
Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK in Pain and Therapy
CHESTERBROOK, PA —Trevena, Inc. (Nasdaq: TRVN) this week announced the publication of an exploratory analysis evaluating the safety of OLINVYK (oliceridine) injection and IV morphine, using data from the OLINVYK Phase …
Read More
Attorney General Shapiro Announces $26 Billion Agreements with Opioid Distributors/Manufacturer
HARRISBURG, PA — Attorney General Josh Shapiro yesterday announced a historic agreement with Cardinal, McKesson, and AmerisourceBergen—the nation’s three major pharmaceutical distributors—and Johnson & Johnson, which manufactured and marketed opioids, …
Read More
Lancaster Doctor Charged With Unlawful Prescribing
LANCASTER, PA — Attorney General Josh Shapiro this week announced that the Office of Attorney General has charged Dr. Robert Mathews with prescribing medications such as Xanax, Adderall, and Subutex …
Read More
Brandywine Hospital Addresses Opioid Overdose in Community
COATESVILLE, PA — Brandywine Hospital shared with the community its plans to address the Opioid Overdose issue in Chester County at an event on June 23, 2021.
Read More
Customs and Border Protection Officers Seize 4.2 Kilos of “Personal Use” Clovidol Opioids
MEMPHIS, TN — On Thursday, June 17, U.S. Customs and Border Protection Officers in Memphis, Tennessee examined a package described in the paperwork by the shipper as “AS PER INVOICE …
Read More
FDA Accepts Braeburn’s Drug Application Resubmission for BRIXADI for Moderate to Severe Opioid Use Disorder
PLYMOUTH MEETING, PA — Braeburn announced that the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release weekly and monthly injection for subcutaneous (SC) use (CIII) for moderate to severe opioid …
Read More Trevena Announces NIH Has Resumed Recruiting Patients for TRV734 Study
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, this week announced …
Read More
Braeburn Resubmits New Drug Application for BRIXADI
PLYMOUTH MEETING, PA — Braeburn announced that this week the New Drug Application (NDA) for BRIXADI (buprenorphine) extended-release injection for subcutaneous (SC) use (CIII) for moderate to severe opioid use …
Read More